ArticleClinical rheumatology2026
Long-term clinical outcomes and safety of rituximab in refractory neuropsychiatric systemic lupus erythematosus: a real-world single-center study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
objectivesTo evaluate the efficacy of rituximab therapy in patients with refractory neuropsychiatric systemic lupus erythematosus (NPSLE).
methodsSeventeen patients with refractory NPSLE who received rituximab therapy at Ruijin Hospital between July 2016 and August 2025 were enrolled. Clinical manifestations and laboratory parameters were collected before and after treatment. Treatment response was evaluated using predefined manifestation-based clinical criteria, and paired longitudinal changes in laboratory parameters were analyzed using the Wilcoxon matched-pairs signed-rank test where data were available.
resultsSixteen of 17 patients (94.1%) achieved significant clinical improvement, while one patient showed partial improvement with reduced seizure frequency. During a follow-up period of 3 to 102 months (median 45 months), none of the surviving patients experienced relapse of neuropsychiatric manifestations. Daily prednisone dose was reduced to a median of 5 mg/day at last follow-up. Rituximab-based treatment was associated with marked depletion of circulating CD19⁺ B cells, reductions in anti-dsDNA antibody titers and SLEDAI-2000 scores, and improvement in complement levels. Two patients died from COVID-19 pneumonia during follow-up, and one patient developed severe Pneumocystis jirovecii and cytomegalovirus pneumonia.
conclusionRituximab was associated with favorable outcomes in refractory NPSLE and may represent an alternative therapeutic option, particularly for patients who are refractory to conventional treatment with glucocorticoids and/or immunosuppressive agents. Key Points • Rituximab-based treatment was associated with clinical improvement in refractory NPSLE. • Sustained relapse-free remission was observed during long-term follow-up after rituximab therapy in patients with refractory NPSLE. • Rituximab was generally well tolerated, though infection risk requires careful monitoring.
Indexed as
Identifiers
42115580What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.